Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (122)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bonnefoy, A.
Right arrow Articles by Chantot, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonnefoy, A.
Right arrow Articles by Chantot, J. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 40, 85-90, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy


ORIGINAL ARTICLES

Ketolides lack inducibility properties of MLS(B) resistance phenotype

A Bonnefoy, AM Girard, C Agouridas and JF Chantot
Antiinfective Research Department, Roussel UCLAF, Romainville, France.

Ketolides belong to a new class of semi-synthetic 14-membered-ring macrolides, which differ from erythromycin A by having a 3-keto group instead of the neutral sugar L-cladinose. The ability of these molecules and their L-cladinose counterparts to induce MLS(B) resistance in staphylococci (one strain) and streptococci (two strains) was investigated using a disc agar susceptibility method as well as measuring induction kinetics. All 14- and 15-membered ring macrolides tested showed inducing activity. In contrast, ketolides were clearly unable to induce MLS(B) resistance, a result consistent with the high in-vitro activity of this new class of antibiotics against erythromycin A-inducible resistant bacteria.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
K. A. Nash, B. A. Brown-Elliott, and R. J. Wallace Jr.
A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1367 - 1376.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. Bailey, T. Chettiath, and A. S. Mankin
Induction of erm(C) Expression by Noninducing Antibiotics
Antimicrob. Agents Chemother., March 1, 2008; 52(3): 866 - 874.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. Gibreel and D. E. Taylor
Macrolide resistance in Campylobacter jejuni and Campylobacter coli
J. Antimicrob. Chemother., August 1, 2006; 58(2): 243 - 255.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Fogarty, R. de Wet, L. Mandell, J. Chang, M. Rangaraju, and R. Nusrat
Five-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization
Chest, October 1, 2005; 128(4): 1980 - 1988.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
N. Kasbekar and P. S. Acharya
Telithromycin: The first ketolide for the treatment of respiratory infections
Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
K. Falzari, Z. Zhu, D. Pan, H. Liu, P. Hongmanee, and S. G. Franzblau
In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis
Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1447 - 1454.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
L. Drago, E. De Vecchi, L. Nicola, A. Colombo, and M. R. Gismondo
Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides
J. Antimicrob. Chemother., August 1, 2004; 54(2): 542 - 545.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. T. Labro, H. Abdelghaffar, and C. Babin-Chevaye
Interaction of the New Ketolide ABT-773 (Cethromycin) with Human Polymorphonuclear Neutrophils and the Phagocytic Cell Line PLB-985 In Vitro
Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1096 - 1104.
[Abstract] [Full Text] [PDF]


Home page
CLIN PEDIATRHome page
D. E. Low, M. E. Pichichero, and U. B. Schaad
Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance
Clinical Pediatrics, March 1, 2004; 43(2): 135 - 151.
[Abstract] [PDF]


Home page
J Antimicrob ChemotherHome page
S. Kaieda, N. Okitsu, H. Yano, Y. Hosaka, R. Nakano, R. Okamoto, H. Takahashi, and M. Inoue
Induction of telithromycin resistance in Streptococcus pneumoniae
J. Antimicrob. Chemother., October 1, 2003; 52(4): 736 - 737.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
J. P. Clark and E. Langston
Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting
Mayo Clin. Proc., September 1, 2003; 78(9): 1113 - 1124.
[Abstract] [PDF]


Home page
J Antimicrob ChemotherHome page
M.-I. Morosini, R. Canton, E. Loza, R. del Campo, F. Almaraz, and F. Baquero
Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin
J. Antimicrob. Chemother., July 1, 2003; 52(1): 50 - 55.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
C. M. Fogarty, S. Kohno, P. Buchanan, M. Aubier, and M. Baz
Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin
J. Antimicrob. Chemother., April 1, 2003; 51(4): 947 - 955.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
G. Ackermann and A. C. Rodloff
Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide
J. Antimicrob. Chemother., March 1, 2003; 51(3): 497 - 511.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
J. M. T. Hamilton-Miller and S. Shah
Activity of ketolide ABT-773 (cethromycin) against erythromycin-resistant Streptococcus pneumoniae: correlation with extended MLSK phenotypes
J. Antimicrob. Chemother., December 1, 2002; 50(6): 907 - 913.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. Leclercq and P. Courvalin
Resistance to Macrolides and Related Antibiotics in Streptococcus pneumoniae
Antimicrob. Agents Chemother., September 1, 2002; 46(9): 2727 - 2734.
[Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
G. Clarebout and R. Leclercq
Fluorescence Assay for Studying the Ability of Macrolides To Induce Production of Ribosomal Methylase
Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2269 - 2272.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
D. E. Low, J. de Azavedo, K. Weiss, T. Mazzulli, M. Kuhn, D. Church, K. Forward, G. Zhanel, A. Simor, and A. McGeer
Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000
Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1295 - 1301.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
F.-J. Schmitz, J. Petridou, H. Jagusch, N. Astfalk, S. Scheuring, and S. Schwarz
Molecular characterization of ketolide-resistant erm(A)-carrying Staphylococcus aureus isolates selected in vitro by telithromycin, ABT-773, quinupristin and clindamycin
J. Antimicrob. Chemother., April 1, 2002; 49(4): 611 - 617.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
V. D. Shortridge, P. Zhong, Z. Cao, J. M. Beyer, L. S. Almer, N. C. Ramer, S. Z. Doktor, and R. K. Flamm
Comparison of In Vitro Activities of ABT-773 and Telithromycin against Macrolide-Susceptible and -Resistant Streptococci and Staphylococci
Antimicrob. Agents Chemother., March 1, 2002; 46(3): 783 - 786.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. Muller-Serieys, P. Soler, C. Cantalloube, F. Lemaitre, H. P. Gia, F. Brunner, and A. Andremont
Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647)
Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3104 - 3108.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
H. Abdelghaffar, D. Vazifeh, and M. T. Labro
Cellular Uptake of Two Fluoroketolides, HMR 3562 and HMR 3787, by Human Polymorphonuclear Neutrophils In Vitro
Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2798 - 2806.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
M.-I. Morosini, R. Canton, E. Loza, M.-C. Negri, J.-C. Galan, F. Almaraz, and F. Baquero
In Vitro Activity of Telithromycin against Spanish Streptococcus pneumoniae Isolates with Characterized Macrolide Resistance Mechanisms
Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2427 - 2431.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
E. Giovanetti, M. P. Montanari, F. Marchetti, and P. E. Varaldo
In vitro activity of ketolides telithromycin and HMR 3004 against Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility
J. Antimicrob. Chemother., December 1, 2000; 46(6): 905 - 908.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
J. M. T. Hamilton-Miller and S. Shah
Patterns of phenotypic resistance to the macrolide-lincosamide-ketolide-streptogramin group of antibiotics in staphylococci
J. Antimicrob. Chemother., December 1, 2000; 46(6): 941 - 949.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. L. Baltch, R. P. Smith, W. J. Ritz, M. A. Franke, and P. B. Michelsen
Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila
J. Antimicrob. Chemother., July 1, 2000; 46(1): 51 - 55.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
W. J. Munckhof, G. Borlace, and J. D. Turnidge
Postantibiotic Suppression of Growth of Erythromycin A-Susceptible and -Resistant Gram-Positive Bacteria by the Ketolides Telithromycin (HMR 3647) and HMR 3004
Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1749 - 1753.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
J. A. Sáez-Nieto and J. A. Vázquez
In Vitro Activities of Ketolides HRM 3647 and HRM 3004, Levofloxacin, and Other Quinolones and Macrolides against Neisseria spp. and Moraxella catarrhalis
Antimicrob. Agents Chemother., April 1, 1999; 43(4): 983 - 984.
[Abstract] [Full Text]


Home page
J Antimicrob ChemotherHome page
A. Rosato, H. Vicarini, and R. Leclercq
Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin
J. Antimicrob. Chemother., April 1, 1999; 43(4): 559 - 562.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. Fernandez-Roblas, R. Calvo, J. Esteban, A. Bryskier, and F. Soriano
The bactericidal activities of HMR 3004, HMR 3647 and erythromycin against Gram-positive bacilli and development of resistance
J. Antimicrob. Chemother., February 1, 1999; 43(2): 285 - 289.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. Torres, M. Zarazaga, C. Tenorio, A. Portillo, Y. Saenz, F. Ruiz, and F. Baquero
In Vitro Activity of the New Ketolide HMR3647 in Comparison with Those of Macrolides and Pristinamycins against Enterococcus spp.
Antimicrob. Agents Chemother., December 1, 1998; 42(12): 3279 - 3281.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.